CN114929240B - 脱氧胞苷的多晶型形式、包含其的组合物和用途 - Google Patents

脱氧胞苷的多晶型形式、包含其的组合物和用途 Download PDF

Info

Publication number
CN114929240B
CN114929240B CN202080073216.4A CN202080073216A CN114929240B CN 114929240 B CN114929240 B CN 114929240B CN 202080073216 A CN202080073216 A CN 202080073216A CN 114929240 B CN114929240 B CN 114929240B
Authority
CN
China
Prior art keywords
ppm
deoxycytidine
mixture
composition
ethanol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080073216.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN114929240A (zh
Inventor
P·格利登
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ushibi Bioscience Co
Original Assignee
Modis Treatment Co
Zhouge Knicks Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Modis Treatment Co, Zhouge Knicks Co filed Critical Modis Treatment Co
Publication of CN114929240A publication Critical patent/CN114929240A/zh
Application granted granted Critical
Publication of CN114929240B publication Critical patent/CN114929240B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/073—Pyrimidine radicals with 2-deoxyribosyl as the saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
CN202080073216.4A 2019-08-19 2020-08-19 脱氧胞苷的多晶型形式、包含其的组合物和用途 Active CN114929240B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962888893P 2019-08-19 2019-08-19
US62/888893 2019-08-19
PCT/US2020/047047 WO2021034962A1 (en) 2019-08-19 2020-08-19 Polymorphic forms of deoxycytidine, compositions comprising the same and uses

Publications (2)

Publication Number Publication Date
CN114929240A CN114929240A (zh) 2022-08-19
CN114929240B true CN114929240B (zh) 2024-10-29

Family

ID=74647126

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080073216.4A Active CN114929240B (zh) 2019-08-19 2020-08-19 脱氧胞苷的多晶型形式、包含其的组合物和用途

Country Status (8)

Country Link
US (1) US11649259B2 (cg-RX-API-DMAC7.html)
EP (1) EP4017502A4 (cg-RX-API-DMAC7.html)
JP (2) JP7769603B2 (cg-RX-API-DMAC7.html)
CN (1) CN114929240B (cg-RX-API-DMAC7.html)
AU (1) AU2020334060B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022002513A2 (cg-RX-API-DMAC7.html)
CA (1) CA3150755A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021034962A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022204555A1 (en) * 2021-03-26 2022-09-29 Zogenix Mds, Inc. Aqueous solutions containing purines and pyrimidines and uses thereof
WO2026082601A2 (en) * 2024-10-15 2026-04-23 UCB Biopharma SRL Method of purification

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002293791A (ja) * 2001-03-30 2002-10-09 Mitsui Chemicals Inc 保護化2’−デオキシシチジン誘導体の精製法
CN107847512A (zh) * 2015-06-17 2018-03-27 纽约市哥伦比亚大学理事会 用于包括线粒体dna耗竭综合症在内的由不平衡的核苷酸库引起的疾病的脱氧核苷疗法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4898936A (en) * 1984-09-24 1990-02-06 Pcr, Inc. 2-deoxyuridines and riboside precursors
JPS61135597A (ja) * 1984-12-06 1986-06-23 Takeda Chem Ind Ltd シチジンおよびデオキシシチジンの製造法
US4900828A (en) * 1988-05-12 1990-02-13 Hoffmann-Laroche Inc. Intermediate compounds and an improved procedure for the synthesis of 2',3'-dideoxycytidine
JP2002255991A (ja) * 2000-12-27 2002-09-11 Mitsui Chemicals Inc 保護化2’−デオキシシチジン誘導体の製造法
CN100424091C (zh) * 2002-06-05 2008-10-08 三井化学株式会社 保护化2’-脱氧胞苷类的精制法
EP1551838B1 (en) * 2002-10-16 2006-08-09 Teva Pharmaceutical Industries Ltd. Method for reducing residual alcohols in crystalline valacyclovir hydrochloride
US9669048B2 (en) * 2012-10-25 2017-06-06 Fresenius Kabi Oncology Limited Stable pharmaceutical composition of 5-aza-2′-deoxycitidine
GB2580963C (en) * 2019-02-01 2025-09-03 Hemispherian As Cancer therapies

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002293791A (ja) * 2001-03-30 2002-10-09 Mitsui Chemicals Inc 保護化2’−デオキシシチジン誘導体の精製法
CN107847512A (zh) * 2015-06-17 2018-03-27 纽约市哥伦比亚大学理事会 用于包括线粒体dna耗竭综合症在内的由不平衡的核苷酸库引起的疾病的脱氧核苷疗法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
M.D. Bratek-Wiewiorowska et al.."Multiforms and behavior of crystalline 2'-deoxycytidine".Journal of Molecular Structure.1998,(第448期),摘要、第177页右栏第1-3段以及图1. *

Also Published As

Publication number Publication date
JP7769603B2 (ja) 2025-11-13
AU2020334060A1 (en) 2022-03-24
US20210054014A1 (en) 2021-02-25
EP4017502A4 (en) 2023-11-01
CN114929240A (zh) 2022-08-19
JP2025160233A (ja) 2025-10-22
EP4017502A1 (en) 2022-06-29
CA3150755A1 (en) 2021-02-25
AU2020334060B2 (en) 2024-11-14
JP2022544831A (ja) 2022-10-21
US11649259B2 (en) 2023-05-16
BR112022002513A2 (pt) 2022-05-03
WO2021034962A1 (en) 2021-02-25

Similar Documents

Publication Publication Date Title
CN110636884B (zh) 新结晶形式
JP2025160233A (ja) デオキシシチジンの多形形態、それを含む組成物および使用
TWI920053B (zh) 2-[3-[4-胺基-3-(2-氟-4-苯氧基-苯基)-1H-吡唑并[3,4-d]嘧啶-1-基]哌啶-1-羰基]-4-甲基-4-[4-(氧環丁烷-3-基)哌-1-基]戊-2-烯腈之晶形
TW201136593A (en) Nucleoside phosphoramidates
US20230151048A1 (en) Crystal form, preparation method, and application of 4′-substituted nucleoside
ES2959891T3 (es) Producción de trans-[tetraclorobis(1H-indazol)rutenato (III)] y composiciones del mismo
JP7235661B2 (ja) 3-ヒドロキシ-4,5-ビス-ベンジルオキシ-6-ベンジルオキシメチル-2-フェニル-2-オキソ-2λ5-[1,2]オキサホスフィナンの結晶多形体
BR112019014825A2 (pt) Composição farmacêutica compreendendo um derivado de oxazina e seu uso no tratamento ou prevenção da doença de alzheimer
CN102770416B (zh) 美他沙酮共晶体
US20260091039A1 (en) Hydrochloric acid salt of a 5-ht2c agonist
CA3148866A1 (en) Dinucleotide compounds for treating cancers and medical uses thereof
CN108218936B (zh) 联苯核苷氨基磷酸酯化合物的异构体及其无定型物
CN105308043B (zh) 丙型肝炎药物的晶型及其制备方法、其药物组合物和用途
WO2023105483A1 (en) Crystalline forms of a 5-aminopyrazole compound useful for treating hbv
KR20210155806A (ko) Pi3k 저해제의 결정다형 및 이의 제조방법
CN116829153A (zh) 治疗流感化合物的晶型及应用
JP6298532B2 (ja) Hcvのヌクレオシド阻害剤の結晶形
JPS60224622A (ja) 強心剤
CN112010905A (zh) 甲磺酸帕拉德福韦晶型及其应用
CN104844592A (zh) 盐酸托烷司琼晶iii型物质及制备方法和其组合物与用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information
CB02 Change of applicant information

Country or region after: U.S.A.

Address after: California, USA

Applicant after: Zhougenix Modis Co.

Address before: California, USA

Applicant before: MODIS treatment Co.

Country or region before: U.S.A.

TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20240411

Address after: California, USA

Applicant after: Zhouge Knicks Co.

Country or region after: U.S.A.

Address before: California, USA

Applicant before: Zhougenix Modis Co.

Country or region before: U.S.A.

GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20241112

Address after: North Carolina, USA

Patentee after: Ushibi Bioscience Co.

Country or region after: U.S.A.

Address before: California, USA

Patentee before: Zhouge Knicks Co.

Country or region before: U.S.A.